Multiple studies have demonstrated that spectro-temporal modulation (STM) detection sensitivity is strongly associated with speech-in-noise reception in hearing-impaired (HI) individuals provided with hearing-aid amplification. Furthermore, a recent study (Zaar et al., 2023b) showed a connection between STM sensitivity and the speech-intelligibility benefit induced by different levels of directionality and noise reduction (DIR+NR) hearing-aid processing. A further significant development has been the introduction of the “Audible Contrast Threshold” (ACT) test (Zaar/Simonsen et al., 2023), a novel STM detection test optimized for clinical use in terms of measurement time, required test equipment, and measurement procedure. The present study, conducted at two sites in Germany and Japan, evaluated the ACT test in a clinical setting using 108 HI participants (81 German; 27 Japanese) with respect to (i) test-retest reliability, (ii) measurement duration, (iii) association with aided speech-in-noise performance, and (iv) connection to DIR+NR speech-intelligibility benefits. The ACT test showed excellent test-retest reliability (Intraclass Correlation Coefficient: 0.951; single-run standard deviation: 0.97 dB) combined with a short measurement duration (1 min 40 s on average). A large spread of ACT values (i.e., contrast losses) was observed across participants. Speech reception thresholds (SRTs) measured with hearing-aid amplification in a realistic spatialized setting with speech and noise interferers showed a large across-participant variability, which was strongly correlated with ACT (R2=0.48). The better-ear 4-frequency pure-tone average (PTA) also strongly correlated with SRTs but to a lesser extent (R2=0.34), while Age was only marginally correlated with SRTs (R2=0.045). Jointly, the three predictors accounted for 57.1% of the SRT variance (R2=0.571), with ACT as the strongest predictor. The SRT benefit induced by strong vs. mild DIR+NR hearing-aid processing was also correlated with ACT (R2=0.22) and to a lesser extent with PTA (R2=0.12), which did not add predictive power to that provided by ACT in a regression model. Overall, the study shows that the ACT test is indeed clinically viable and that ACT provides a highly useful measure of STM sensitivity that is predictive of HI individuals’ performance in life-like speech reception with hearing aids, including effects of advanced DIR+NR hearing-aid processing.